MedTrace Logo

Bioavailability of Fish Oils: Emulsified Versus Capsular Triglyceride

NCT01488747 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2018-08-03

No results posted yet for this study

Summary

The primary objective of this investigation is to determine the relative percentage and rate of incorporation of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and total omega-3 (n-3) fatty acids after ingestion of 4 emulsified flavored triglyceride fish oil supplements versus an encapsulated triglyceride in defined plasma lipid pools.

The primary endpoints to be evaluated include the fatty acid composition of plasma lipids before and after consumption of a single dose of emulsified triglyceride based fish oil and triglyceride of similar n-3 compositions in capsule form. The investigators will measure changes in plasma phospholipid, and chylomicron fatty acids.

Conditions

  • Healthy Adults

Interventions

DIETARY_SUPPLEMENT

Coromega Omega-3 Squeeze

660 mg EPA, 434 mg DHA

DIETARY_SUPPLEMENT

Coromega Nectar

660 mg EPA, 436 mg DHA

DIETARY_SUPPLEMENT

Barleans Swirl

660 mg EPA, 660 mg DHA

DIETARY_SUPPLEMENT

Nordic Omega-3 Softgel

660 mg EPA, 440 mg DHA

Sponsors & Collaborators

  • USDA Grand Forks Human Nutrition Research Center

    lead FED

Principal Investigators

  • Susan Raatz, PhD, RD · USDA Grand Forks Human Nutrition Research Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2012-10-31
Completion
2016-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01488747 on ClinicalTrials.gov